Boston, MA -- November 17, 2006 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced that it has signed a three-year agreement with Schering Corporation, a subsidiary of Schering-Plough Corporation, to provide and implement its OneSource® maintenance solution at four Schering-Plough laboratory sites in New Jersey. This represents the extension of an existing relationship between these companies for analytical and life sciences instrumentation and related services.
OneSource offers a comprehensive, flexible business solution for all lab equipment maintenance and asset management activities. Through consolidated and proactive management, OneSource provides customers with better control of their maintenance costs and helps to improve laboratory productivity through increased uptime.
“Schering-Plough's decision demonstrates its position as a leader in the industry, capitalizing on the growing trend toward laboratory management solutions that are flexible and deliver a high level of productivity,” said Robert F. Friel, president of PerkinElmer Life and Analytical Sciences. “OneSource is a proven solution in that regard.”
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma and medical imaging. Photonics markets include sensors and specialty lighting.